Develops nanoparticles for cancer treatment, focusing on nanomedicine and radioenhancement therapies.
Nanobiotix S.A., headquartered in Paris, France, is an innovative clinical-stage biotechnology company specializing in advancing cutting-edge therapies for the treatment of cancer. Established in 2003, Nanobiotix focuses on developing transformative product candidates designed to enhance oncological treatment outcomes.
At the forefront of its portfolio is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles. NBTXR3 is tailored for the treatment of a wide range of cancers, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has strategically partnered with LianBio to develop and commercialize NBTXR3 across Greater China, South Korea, Singapore, and Thailand, underscoring its global commitment to expanding treatment options for cancer patients.
Through its dedication to scientific excellence and strategic collaborations, Nanobiotix continues to push the boundaries of oncology research and innovation. By leveraging nanotechnology and precision medicine, Nanobiotix aims to revolutionize cancer therapy, providing new hope and improved outcomes for patients worldwide.